SLC5A2 and atrial fibrillation: Moreover, three recent cardiac remodelling trials, collectively, showed that SGLT2 inhibition reduced left atrial size in patients with HFrEF, an effect supporting the possibility of a beneficial effect on incident AF.32, 33, 34